Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow DBV Technologies S.A.

Get SEC filing alerts via email and in your feed for DBV Technologies S.A.

DBVT DBVTF

DBV Technologies S.A.

About DBV Technologies S.A.

DBV Technologies is a clinical-stage biopharmaceutical company developing innovative immunotherapies for food allergies and immune-related conditions. Its proprietary Viaskin platform delivers allergens via skin patches to induce desensitization safely and non-invasively. Focused on peanut allergy, the company advances its products through clinical trials targeting children, aiming to provide effective, convenient treatments that address unmet medical needs in allergy management.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from DBV Technologies S.A.

1
1
DBV Technologies S.A. DBV Technologies Reports $47.6 Million Net Loss in Q1 2026 Amid Increased R&D Expenses

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
DBV Technologies S.A. DBV Technologies Reports Increased Operating Income but Wider Net Loss for 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
DBV Technologies S.A. DBV Technologies Reports Q3 2025 Financial Results with Increased Net Loss and Operating Income

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
DBV Technologies S.A. DBV Technologies Reports Q2 2025 Financial Results with Increased Net Loss and Improved Cash Reserves

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
DBV Technologies S.A. DBV Technologies Reports $27.1 Million Net Loss in Q1 2025, Secures $306.9 Million Financing

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
DBV Technologies S.A. DBV Technologies Reports $113.9 Million Net Loss for 2024, Focuses on Viaskin Peanut Development

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
DBV Technologies S.A. DBV Technologies Reports Significant Financial Challenges, Net Loss of $30.4 Million in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments